This has raised the prospect of a HIV-1 vaccine that mediates protection via HLA-E-restricted CD8+ T cells, and there is now great interest in exploiting HLA-E for both vaccine and immunotherapy strategies for both infectious diseases and tumours (16–20). Here, HLA-E is linked to neoplasm.